A clinical trial involving 767 participants was carried out to investigate the role of suPAR in adult patients with COVID-19 (NCT04590794), and UPAR has been identified as a predictor of disease progression biomarkers in COVID-19 [79, 80]. The gene discussed is PLAUR; the disease is COVID-19.